Furnish Medical Care
Clinical trials furnish medical care and the drug of interest without cost to the participant
Clinical trials offer free medication and close monitoring but involve frequent visits and may not provide the new drug immediately.
Important things to know about Clinical Trials
Placebo Controlled
Many Clinical trials are “placebo controlled” meaning that you have roughly equal chance of getting the mediation vs a placebo. HOWEVER, most trials allow a “cross over” so after the initial phase you can get the medication at no cost.
Frequent Follow Up
Clinical trials require more frequent follow up. Clinical trials follow patients very closely and monitor several parameters, so often the visits are more frequent and take longer than a regular doctor’s appointment. This is something to be aware of before starting a clinical trial.
Medication: Approved or New
Clinical trials can be for already FDA approved medications such as Tepezza or for new medications that are not yet FDA approved.
Contact Us
For more information about TED clinical trials, please contact us and a coordinator will get back to you in one or two business days.
Current TED Clinical Trials
Listing of CURRENT TED clinical Trials recruiting patients (for the most up-to-date info www.clinicaltrials.gov.)
Observational Characterization of the Treatment Course of Patients With Thyroid Eye Disease
- Status: Active/Enrolling
- SPONSOR: Thrive Health
- Synopsis:
- Patients who are diagnosed with Thyroid Eye Disease (TED) are asked to take part in the clinical research study. Subjects will receive the TED treatment that is considered to be most appropriate by the study doctor, according to their medical and disease history, and which the subject considers acceptable.
- This is a noninterventional study which means that subjects will only be observed. No treatment, procedure, or test will be performed as part of the study. No aspect of the study is experimental.
- The purpose of the study is to evaluate standard-of-care (SOC) treatment for TED in a real-world setting, the effectiveness of the treatment in terms of protrusion of the eyeball (proptosis), to show if the SOC treatment has any effect on eye anatomy and function and if the appearance of the subject’s eyes will change, and to evaluate the tolerability of SOC in subjects with TED.
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease
- Status: Active/Enrolling
- Company: Vasaragen/ Sling
- Eligibility Summary:
- Diagnosis of moderate to severe TED within 1 year prior to screening visit.
- Euthyroid or subclinical hyperthyroidism. No previous corneal decompensation, orbital irradiation, or orbital surgery.